More on ACIU
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.68 |
|
|||
| Open | $2.69 | ||||
| 52 Wk High | $19.97 | ||||
| 52 Wk Low | $10.36 | ||||
| Day High | $2.81 | ||||
| Day Low | $2.63 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 68,462 | ||||
- H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)
- Form 6-K AC Immune SA For: Aug 20
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
- Form 6-K AC Immune SA For: Aug 11
- AC Immune gets FDA fast track for Parkinson's drug ACI-7104
- AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
- Form 6-K AC Immune SA For: Jun 30
- AC Immune First Half 2026 Financial and Corporate Update
- AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Entities mentioned with ACIU
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Jefferies & Co | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
